Revolution Medicines grants equity to Xiaolin Wang

Revolution Medicines, Inc. reported that officer Xiaolin Wang received equity awards on March 1, 2026.

Rhea-AI Filing Summary

Revolution Medicines, Inc. reported that officer Xiaolin Wang received equity awards on March 1, 2026. Wang was granted stock options for 34,000 shares at an exercise price of $0.00 and 15,100 shares of common stock, both as awards rather than open-market purchases.

Following the common stock grant, Wang directly owned 118,073 common shares, which includes 54,464 restricted stock units and 652 shares acquired under the employee stock purchase plan. The option award vests in equal monthly installments over four years starting March 1, 2026, contingent on continued service.

Insider Trade Summary

Grant/Award: 49,100 shares

Grant/Award 2 txns

Insider Wang Xiaolin

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	34,000	$0.00	$0.00
Grant/Award	Common Stock	15,100	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 34,000 contracts (Direct); Common Stock — 118,073 shares (Direct)

Footnotes (3)

1. F1. Includes 54,464 restricted stock units.
2. F2. Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.
3. F3. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Xiaolin Wang receive from Revolution Medicines (RVMD)?

Xiaolin Wang received stock options for 34,000 shares and 15,100 shares of common stock as equity awards. These were granted at an exercise price of $0.00 per share and represent compensation, not open-market buying or selling of Revolution Medicines stock.

How many Revolution Medicines (RVMD) shares does Xiaolin Wang own after this Form 4?

After the reported grant, Xiaolin Wang directly owns 118,073 shares of Revolution Medicines common stock. This figure includes 54,464 restricted stock units and 652 shares previously acquired under the company’s employee stock purchase plan, reflecting total direct equity exposure reported in this filing.

What is the vesting schedule for Xiaolin Wang’s 34,000 Revolution Medicines stock options?

The 34,000 stock options vest in 48 equal monthly installments starting March 1, 2026. One forty-eighth of the options vest each month so that all options are fully vested and exercisable by the fourth anniversary, subject to Xiaolin Wang’s continued service with the company.

Were Xiaolin Wang’s Revolution Medicines equity awards open-market purchases?

No, the equity awards were not open-market purchases. The Form 4 classifies both the 34,000 stock options and 15,100 common shares as grants or awards with a transaction code "A", indicating compensatory acquisitions rather than shares bought or sold on the open market.

What does transaction code "A" mean in the Revolution Medicines (RVMD) Form 4 for Xiaolin Wang?

Transaction code "A" indicates a grant, award, or other acquisition of securities. In this case, it reflects compensatory grants of 34,000 stock options and 15,100 common shares to Xiaolin Wang, rather than discretionary buying or selling of Revolution Medicines stock in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 09:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wang Xiaolin

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		15,100	A	$0	118,073(1)(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$102.02	03/01/2026		A		34,000		(3)	02/28/2036	Common Stock	34,000	$0	34,000	D

Explanation of Responses:

1. Includes 54,464 restricted stock units.

2. Includes 652 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2025.

3. One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2026 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

EVP, Clinical Development

	/s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.